全文获取类型
收费全文 | 29357篇 |
免费 | 2838篇 |
国内免费 | 2155篇 |
专业分类
耳鼻咽喉 | 216篇 |
儿科学 | 405篇 |
妇产科学 | 343篇 |
基础医学 | 3378篇 |
口腔科学 | 530篇 |
临床医学 | 3931篇 |
内科学 | 4497篇 |
皮肤病学 | 264篇 |
神经病学 | 1430篇 |
特种医学 | 1268篇 |
外国民族医学 | 12篇 |
外科学 | 3345篇 |
综合类 | 4795篇 |
现状与发展 | 6篇 |
一般理论 | 3篇 |
预防医学 | 1905篇 |
眼科学 | 681篇 |
药学 | 3131篇 |
27篇 | |
中国医学 | 1581篇 |
肿瘤学 | 2602篇 |
出版年
2024年 | 91篇 |
2023年 | 437篇 |
2022年 | 1092篇 |
2021年 | 1362篇 |
2020年 | 1025篇 |
2019年 | 933篇 |
2018年 | 960篇 |
2017年 | 911篇 |
2016年 | 935篇 |
2015年 | 1315篇 |
2014年 | 1601篇 |
2013年 | 1460篇 |
2012年 | 1941篇 |
2011年 | 2327篇 |
2010年 | 1489篇 |
2009年 | 1155篇 |
2008年 | 1498篇 |
2007年 | 1572篇 |
2006年 | 1513篇 |
2005年 | 1474篇 |
2004年 | 1126篇 |
2003年 | 1139篇 |
2002年 | 1018篇 |
2001年 | 863篇 |
2000年 | 793篇 |
1999年 | 745篇 |
1998年 | 433篇 |
1997年 | 502篇 |
1996年 | 333篇 |
1995年 | 295篇 |
1994年 | 232篇 |
1993年 | 189篇 |
1992年 | 228篇 |
1991年 | 212篇 |
1990年 | 182篇 |
1989年 | 164篇 |
1988年 | 133篇 |
1987年 | 136篇 |
1986年 | 119篇 |
1985年 | 76篇 |
1984年 | 50篇 |
1983年 | 28篇 |
1982年 | 16篇 |
1981年 | 17篇 |
1980年 | 25篇 |
1979年 | 45篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
4.
5.
6.
7.
8.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
9.
HIV-1 infection usually leads to systemic chronic inflammation that is associated with gut microbial translocation. The recently defined group 3 innate lymphoid cells (ILC3s) are critical for maintenance of intestinal barrier function; however, it is not clear whether and how HIV-1 infection influences the function of these cells. In this issue of the JCI, Zhang and colleagues present compelling evidence that the survival and function of ILC3s are dramatically impaired by HIV-1 infection. The authors provide evidence that HIV-1 infection induces persistent activation of plasmacytoid dendritic cells (pDCs) and production of type I IFNs, which together increase expression of death receptor CD95 on ILC3s and thereby promote subsequent ILC3 apoptosis. Together, these results identify a mechanism that explains the impaired intestinal barrier function that results from chronic HIV-1 infection and shed light on the role of pDCs in HIV-1 immunopathogenesis and therapy. 相似文献
10.